Mail & Guardian
Mail & Guardian
vaccine side effectslatest news & developments
A healthcare worker administers a SINOVAC Covid-19 vaccine on a minor during the Numolux/SINOVAC Paediatric Covid-19 Vaccine Clinical Trial at the Sefako Makgatho Health Sciences University in Pretoria, on September 10, 2021. – The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic COVID-19 cases in children and adolescents aged 6 months to 17 years. Efficacy will also be evaluated against hospitalization and severe COVID-19 cases. The study worldwide will enroll 14 000 children and adolescents in various pediatric age group cohorts across 5 countries (South Africa, Chile, Philippines, Malaysia and Kenya). (Photo by Phill Magakoe / AFP)
12 YEARS AND OLDER

Pfizer vaccine approved for children older than 12, but roll-out not yet on the way

Vulnerable older groups remain a priority for the health department, so no Covid-19 jabs for children for now

  • Marcia Zali
4 min read